Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Enhance Market Position

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a 1-for-12 reverse stock split of its common stock, effective August 5, 2025. This strategic move, approved by shareholders on July 9 and ratified by the board on July 11, is designed to optimize market dynamics, enhance the company's appeal to investors, and align trading conditions with the interests of its shareholders. Following the split, shares will trade on the NYSE American under the existing ticker 'CLDI' but with a new CUSIP number of 320703 408.

The reverse stock split will convert every 12 pre-split shares into one post-split share, with fractional shares being rounded up to the nearest whole share at the participant level. This adjustment will proportionately affect outstanding options, warrants, and equity plan shares, though it will not alter the par value or the number of authorized shares. The decision reflects Calidi Biotherapeutics' commitment to strengthening its market position and ensuring long-term growth.

Calidi Biotherapeutics is at the forefront of developing targeted genetic medicine delivery platforms, with a focus on immuno-oncology. The company's innovative stem cell-based platforms are designed to carry payloads of oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors. This reverse stock split is a testament to the company's dedication to advancing its clinical-stage off-the-shelf, universal cell-based delivery platforms, which aim to improve efficacy and patient safety in cancer treatment.

The implications of this announcement are significant for investors and the biotechnology industry. By implementing a reverse stock split, Calidi Biotherapeutics is taking a proactive step to enhance its stock's marketability and appeal to a broader range of investors. This could potentially lead to increased liquidity and a more favorable trading environment, benefiting both the company and its shareholders. As Calidi Biotherapeutics continues to innovate in the field of immuno-oncology, this strategic financial maneuver underscores its commitment to achieving sustainable growth and delivering value to its stakeholders.